Skip to main content
. 2020 Feb 20;12(3):485–495. doi: 10.4168/aair.2020.12.3.485

Table 1. Demographic and clinical characteristics of the study patients.

Factors All (n = 3,240) Mild and moderate asthma exacerbation (n = 2,577) Severe and life-threatening asthma exacerbation (n = 652) P
Age (yr) 57 (44–67) 57 (44–64) 59 (49.3–68) 0.40
Sex
Male 1,369 (42.3) 1,067 (41.4) 299 (45.9) 0.04
Disease course (yr) 8 (2–20) 7 (2–20) 10 (3–20) < 0.01
Smoking status (n = 3,230)
Current smokers 337 (10.4) 252 (9.8) 84 (12.9) 0.02
Ex-smokers 433 (13.4) 319 (12.4) 114 (17.5) < 0.01
Non-smokers 2,470 (76.2) 2,006 (77.8) 454 (69.6) < 0.01
History of hospitalization or emergency care visit for asthma in the past year 1,359 (41.9) 1,061 (41.2) 294 (45.1) 0.07
Treatment before admission
Using daily controllers regularly 907 (28.0) 711 (27.6) 194 (29.8) 0.27
Not currently using ICS 1,287 (39.7) 1,031 (40.0) 254 (39.0) 0.62
Currently using or having recently stopped using OCS 161 (5.0) 119 (4.6) 41 (6.3) 0.08
History of non-adherence 1,067 (32.9) 847 (32.9) 216 (33.1) 0.09
Comorbidities
Hypertension 733 (22.6) 544 (21.1) 187 (28.7) < 0.01
Diabetes mellitus 248 (7.7) 186 (7.2) 61 (9.4) 0.08
Coronary heart disease 248 (7.7) 196 (7.6) 51 (7.8) 0.80
COPD 421 (13.0) 298 (11.6) 123 (18.9) < 0.01
Bronchiectasis 119 (3.7) 92 (3.6) 27 (4.1) 0.50
OSAHS 56 (1.7) 47 (1.8) 8 (1.2) 0.30
Allergic rhinitis 477 (14.7) 381 (14.8) 94 (14.4) 0.81
Sinusitis 109 (3.4) 81 (3.1) 28 (4.3) 0.15
Nasal polyps 37 (1.1) 26 (1.0) 11 (1.7) 0.15
Food allergy 49 (1.5) 32 (1.2) 17 (2.6) 0.01
GERD 46 (1.4) 42 (1.6) 4 (0.6) 0.08
Anxiety/depression 24 (0.7) 21 (0.8) 3 (0.5) 0.50
Triggering factor
Acute upper airway infection 1,370 (42.3) 1,087 (42.2) 283 (43.4) 0.60
Weather changes 738 (22.8) 606 (23.5) 133 (20.4) 0.10
Noxious gas 140 (4.3) 111 (4.3) 29 (4.4) 0.90
Allergen exposure 115 (3.5) 100 (3.9) 15 (2.3) 0.07
Strenuous exercise 57 (1.8) 50 (1.9) 7 (1.1) 0.20
Air pollution 49 (1.5) 41 (1.6) 8 (1.2) 0.60

Values are presented as median with quartiles or number of patients (%).

ICS, inhaled corticosteroid; OCS, oral corticosteroid; COPD, chronic obstructive pulmonary disease; OSAHS, obstructive sleep apnea and hypoventilation syndrome; GERD, gastroesophageal reflux disease.